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Abstract
Objective: We conducted this prospective study to expand available information in relation to
serum phosphate levels in treatment of acute asthma. A -adrenergic agonist, salbutamol, was
used for this purpose.
Material and methods: Twenty-six patients who met the inclusion criteria as; age over 16 years,
asthma history, and an acute exacerbation were included. Serum blood urea nitrogen, creati-
nine, glucose were within normal limits in all the patients. None of the patients were on chronic
theophylline therapy. Baseline serum phosphate and potassium levels were measured. Nebu-
lized salbutamol (2.5mg) was used three times at every hour. After 60min, serum phosphate
and potassium levels were measured.
Results: Serum phosphate levels decreased from 3.7± 0.9mg/dL (baseline) to 3.6±0.9mg/dL
at 60min. This decrease was not statistically signiﬁcant (p = 0.373). Serum potassium lev-
els decreased signiﬁcantly (p < 0.001) from 4.6± 0.7mmol/L (baseline) to 4.3± 0.7mmol/L
(60min).
Conclusion: Administration of nebulized salbutamol during the emergency treatment of acute
exacerbation of asthma is not associated with a statistical decrease in serum phosphate. There
was signiﬁcant hypokalemia. This study indicates that a further study is needed to elucidate
the clinical signiﬁcance of nebulized salbutamol on serum phosphate.
© 2012 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights
reserved.∗ Corresponding author.
E-mail address: drkarakus@yahoo.com (A. Karakus).
873-2159/$ – see front matter © 2012 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights reserved.
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Salbutamol Nebulizado na Asma: Efeitos nos níveis de Potássio e Fosfato Sérico aos 60
minutos
Resumo
Objetivo: Levámos a cabo este estudo prospetivo para ampliar a informac¸ão disponível relati-
vamente aos níveis de fosfato sérico no tratamento de asma aguda. Foi utilizado um agonista
-adrenérgico, salbutamol, para este efeito.
Materiais e métodos: Foram incluídos 26 doentes que cumpriam os critérios de inclusão de:
idade superior a 16 anos, história de asma, incluindo uma exacerbac¸ão aguda. A ureia do
soro sanguíneo, creatinina e glucose estavam nos limites normais em todos os doentes. Nen-
hum dos doentes era submetido a terapia crónica de teoﬁlina. Os níveis da base de referência
de fosfato e potássio sérico foram medidos. O nebulizador de salbutamol (2,5mg) era usado
3 vezes por hora. Após 60 min, os níveis da base de referência de fosfato e potássio sérico eram
medidos.
Resultados: Os níveis de fosfato sérico diminuíram de 3,7± 0,9mg/dL (base de referência) para
3,6± 0,9mg/dL aos 60 min. Esta reduc¸ão não era estatisticamente signiﬁcativa (p = 0,373). Os
níveis de potássio sérico diminuíram signiﬁcativamente (p < 0,001) de 4,6± 0,7mmol/L (base
de referência) para 4,3± 0,7mmol/L aos 60 min.
Conclusão: A administrac¸ão de salbutamol nebulizado durante o tratamento de urgência de
uma exacerbac¸ão aguda de asma não está associada a uma diminuic¸ão estatística do fosfato
sérico. Ocorreu uma hipocalemia signiﬁcativa. Este estudo indica que é necessário um estudo
adicional para esclarecer o signiﬁcado clínico do salbutamol nebulizado no fosfato sérico.
© 2012 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L. Todos os
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Introduction
Asphyxia is responsible for the majority of deaths in patients
with acute asthmatic crisis, and the adverse effects of medi-
cal treatments are also important in terms of the deaths.1
Nebulized -adrenergic agonists are the mainstay of treat-
ment for acute exacerbation of asthma in the emergency
setting.2 -Adrenergic agonists (BAA) have side effects such
as tremor, palpitations, tachycardia, and anxiety.3 There
are several studies that demonstrate a statistically signif-
icant decrease in serum potassium and magnesium after
BAA administration.4--7 In addition, there are also some stud-
ies regarding the BAA induced hypophosphatemia.8--11 In the
current research, our aim is to investigate Serum Potassium
and Phosphate Levels at the 60min after administration of
Nebulized Salbutamol for Asthma.
Materials and methods
This prospective study is conducted in patients with asth-
matic attack in the emergency department. Patients were
treated with a BAA-salbutamol -- according to a study
protocol that was approved by the local ethical commit-
tee. Informed consent was obtained from all the patients.
Baseline data including age, sex, clinical history, and the
medications used were recorded. All patients included in
the study met the criteria as: age >16 years, a history
of acute exacerbation of asthma (dyspnea, cough and, on
examination, wheezing). Patients with respiratory failure,
altered mental status, renal failure, diabetes mellitus, and
cirrhosis were excluded. Patients using alcohol, diuretics,
theophylline, aminophylline, antidiabetic, and antihyper-
tensive drugs were also excluded. The samples had BAA at
T
T
yeast four hours before the admission. The severity of the
xacerbation determines the treatment modality. Indices of
everity including particularly PEF, pulse rate, respiratory
ate, and pulse oximetry, had to be monitored during treat-
ent. The exacerbation severity was deﬁned according to
he Global Strategy for Asthma Management and Prevention
011.12
All the patients were monitorized by continuous elec-
rocardiograhy, and arterial oxygen saturation by pulse
ximetry with a ﬁnger oximeter. The baseline peak expi-
atory ﬂow rate was measured. An intraveneous (i.v.) line
or repeated blood sampling was established and baseline
aboratory assay which included serum phosphate, creati-
ine, blood urea nitrogen, glucose, potassium levels was
erformed. Patients were given initial nebulized treatment
f salbutamol (2.5mg).
Nebulized salbutamol (2.5mg) was used three times
uring the ﬁrst hour. After the third administration of
albutamol, serum phosphate and potassium levels were
ssessed.
None of the patient received magnesium, potassium,
hosphate, corticosteroids, theophylline, and i.v. dextrose
r saline during the study period.
The mean and standard deviation were calculated for
aseline and subsequent measure of phosphate and potas-
ium. Paired-t test was used for analyzing the changes in
ase of phosphate and potassium levels. p-Value <0.05 was
onsidered statistically signiﬁcant.
esultswenty-six patients were enrolled during the study period.
he mean patient age was 58.8± 10.3 years (range 35--74
ears), with 11 female and 15 male asthmatic patients.
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Figure 1 Serum phosphate levels did not decrease signiﬁ-
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Rantly during the treatment (p = 0.373). Serum potassium levels
ecreased signiﬁcantly (p < 0.001).
ll the patients had moderate asthmatic attack. The pro-
ocol included the usage of oxygen if arterial oxygen
aturation (Sao2) decreased to less than 92%. However,
uring the study, all patients had Sao2 values above 92%.
here was no change in ECG monitorization related to
ypokalemia in the patients. In the emergency depart-
ent, all patients received three doses of nebulized
albutamol therapy (2.5mg, every 20min). Theophylline
nd corticosteroids were not administered in the emer-
ency department during the study. Neither intraveneous
extrose nor saline solution was used during the study
eriod.
There was an average duration of symptoms of 30± 35 h
range 2--55) before seeking medical attention. Mean base-
ine peak expiratory ﬂow rate averaged 210± 110 L/min
range 100--320 L/min).
Although serum phosphate levels decreased from a mean
f 3.7± 0.9mg/dL at baseline to 3.6± 0.9mg/dL at 60min,
o signiﬁcant decrease was found (Fig. 1).
Serum potassium levels decreased signiﬁcantly from
.6± 0.7 (baseline) to 4.3± 0.7mmol/L (60min) (p < .001)
Fig. 1).
iscussion
he aim of this study was to add more data to the informa-
ion concerning the serum phosphate and potassium changes
uring intensive treatment of acute asthma with salbutamol.
In this study, salbutamol use was accompanied by a sig-
iﬁcant decrease in serum potassium levels. Our observation
egarding BAA related hypokalemia is consistent with most
f the previous studies.4--7 The principal action of BAA is to
timulate the BAA that are associated with the membrane-
ound sodium-potassium ATPase. Activation of this enzyme
esults in a direct potassium inﬂux into cells.
In this report, salbutamol was given according to
he standard emergency medical protocols, and it wasM. Sahan et al.
ot accompanied by signiﬁcant decrease in serum phos-
hate. Serum phosphate levels decreased from a mean of
.7± 0.9mg/dL at baseline to 3.6± 0.9mg/dL at 60min. No
igniﬁcant correlation was found. This result is not consis-
ent with previous studies.
There are some differences between our study and previ-
us studies. Firstly, we administered only a BAA-salbutamol.
e did not use i.v. ﬂuids, theophylline, and corticosteroids
hich may have an effect on serum phosphate levels.
Secondly, our patients were not receiving theophylline,
iuretics, antihypertensive, and antidiabetics before they
rrived at the emergency department.
In one study BAA induced hypophosphatemia, but BAA
nd other bronchodilator drugs were used together.8
In a different study, BAA decreased serum phosphate,
esides albuterol, other bronchodilator agents such as
heophylline, atropin, corticosteroids, and i.v. ﬂuids were
dministered.11
In another study, it is reported that hypophosphatemia
nduced by albuterol is due to the parenteral albuterol
dministration.13
In Massara et al’s study, i.v. infusion of salbutamol caused
ypophosphatemia.10
In the current study, we used only nebulized salbutamol.
ther drugs that may affect serum phosphate levels such
s theophylline, corticosteroids and IV ﬂuids were not used.
herefore, this preliminary report indicates that a further
tudy aimed at elucidating the clinical effect of nebulized
albutamol on serum phosphate is required.
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